Sugi Predict

Sugi Predict / Targets / SREBF2

SREBF2

Sterol regulatory element-binding protein 2 · Q12772 · SREBF2 on Sugi Atlas →

11,744 patent compounds predicted against SREBF2, 9,268 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2296943 SCHEMBL2296943 0.64 13/20
SCHEMBL1435535 SCHEMBL1435535 0.50 12/20
SCHEMBL1436189 SCHEMBL1436189 0.49 12/20
SCHEMBL539420 SCHEMBL539420 0.50 11/20
SCHEMBL1400294 SCHEMBL1400294 0.50 11/20
SCHEMBL487201 SCHEMBL487201 0.44 10/20
Protionamide Protionamide (SCHEMBL74572) 0.40 10/20
SCHEMBL1507007 SCHEMBL1507007 0.50 9/20
SCHEMBL1400165 SCHEMBL1400165 0.46 9/20
SCHEMBL1400597 SCHEMBL1400597 0.44 8/20
SCHEMBL1818589 SCHEMBL1818589 0.55 4/20
SCHEMBL1180965 SCHEMBL1180965 0.59 3/20
SCHEMBL1505287 SCHEMBL1505287 0.65 2/20
SCHEMBL1181045 SCHEMBL1181045 0.62 2/20
SCHEMBL1181195 SCHEMBL1181195 0.58 2/20
SCHEMBL1774137 SCHEMBL1774137 0.58 2/20
SCHEMBL299048 SCHEMBL299048 0.49 2/20
SCHEMBL2096526 SCHEMBL2096526 0.49 2/20
SCHEMBL2092693 SCHEMBL2092693 0.43 2/20
SCHEMBL177267 SCHEMBL177267 1.00 1/20

Clinical trials — most relevant to SREBF2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease PHASE4COMPLETED
Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes PHASE4COMPLETED
Mechanisms of Lipodystrophy in HIV-Infected Pateints PHASE4COMPLETED
Oltipraz for Liver Fat Reduction in Patients With Non-alcoholic Fatty Liver Disease Except for Liver Cirrhosis PHASE3COMPLETED
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis PHASE2ACTIVE_NOT_RECRUITING
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer PHASE2COMPLETED
Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation PHASE2UNKNOWN
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Choline Effects - Pre-symptomatic AD PHASE1COMPLETED
Statin Therapy and COVID-19 Infection nanCOMPLETED
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes nanCOMPLETED
The Role of Sugars in Fat Accumulation in the Liver nanRECRUITING
Fish Oil and Nonalcoholic Fatty Liver Disease (NAFLD) Study nanCOMPLETED
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy nanNOT_YET_RECRUITING
Omics-based Predictors of NAFLD/Potential NASH nanUNKNOWN
Response to an Intervention With Omega-3 (RIO - Study) nanCOMPLETED
Mechanisms of Glucose Lowering Effect of Colesevelam HCl nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Genetic and Environmental Determinants of Triglycerides (GOLDN) nanCOMPLETED
A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH) nanWITHDRAWN
A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome nanCOMPLETED
Role of Obeticholic Acid in the Patients of NAFLD With Raised ALT nanCOMPLETED
Gene Expression in Obesity and Insulin Resistance nanCOMPLETED
Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids nanRECRUITING
Genetic-specific Effects of Fructose on Liver Lipogenesis nanCOMPLETED
HIV Reverse Cholesterol Transport Study nanUNKNOWN
Observational Study to Assess Glycosylated Hemoglobin Changes After 6 Months of Treatment With Pioglitazone. nanCOMPLETED
The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux nanCOMPLETED
Nasturtium (Tropaeolum Majus L) Intake and Biochemical Parameters in Pre-diabetic Subjects in Bogota Colombia nanCOMPLETED
Epigenomic and Metabolomic Signatures of APOA2 Gene by Saturated Fat Interaction nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SREBF2 binder may also engage these)

ProteinNameSimilarity
Q3U1N2 — 1.000 Q3U1N2 →
Q3T1I5 — 1.000 Q3T1I5 →
Q60429 — 1.000 Q60429 →
Q6GQ26 — 1.000 Q6GQ26 →
A3KNA7 — 0.998 A3KNA7 →
NFRKB Nuclear factor related to kappa-B-binding protein 0.991 landscape →
Q6PIJ4 — 0.988 Q6PIJ4 →
Q2HJE1 — 0.988 Q2HJE1 →
Q7TMQ7 — 0.988 Q7TMQ7 →
Q32N92 — 0.987 Q32N92 →
WDR91 WD repeat-containing protein 91 0.986 landscape →
Q58CP9 — 0.986 Q58CP9 →
Q91857 — 0.986 Q91857 →
P84903 — 0.986 P84903 →
Q4V9P9 — 0.985 Q4V9P9 →
Q1LYM3 — 0.985 Q1LYM3 →
STIM1 Stromal interaction molecule 1 0.985 landscape →
Q58HI1 — 0.985 Q58HI1 →
Q8WUM0 — 0.985 Q8WUM0 →
Q7Z3E5 — 0.985 Q7Z3E5 →
P70302 — 0.985 P70302 →
Q3UB74 — 0.985 Q3UB74 →
Q5PRF9 — 0.984 Q5PRF9 →
O95475 — 0.984 O95475 →
Q96C34 — 0.984 Q96C34 →
Q5PQS3 — 0.984 Q5PQS3 →
P50569 — 0.984 P50569 →
Q6INP8 — 0.984 Q6INP8 →
Q5F259 — 0.984 Q5F259 →
A1A4J7 — 0.984 A1A4J7 →